The objective of this study was to investigate confirmed progression independent of relapse activity in relapsing-remitting multiple sclerosis patients under long-term natalizumab treatment. We performed a retrospective, cross-sectional study of clinical data captured between 1994 and 2019 at two German multiple sclerosis tertiary referral centres. Data files of all relapsing-remitting multiple sclerosis patients treated with natalizumab for ≥24 months were analysed. Confirmed progression independent of relapse activity was defined as ≥12 week confirmed disability progression on a roving Expanded Disability Status Scale reference score by 1 point in patients with an Expanded Disability Status Scale score ≤3 or 0.5 in patients with an Expanded Disability Status Scale score ≥3.5 in the absence of a relapse. Cox proportional hazard models were used to analyse the probability of developing confirmed progression independent of relapse activity depending on both disease and natalizumab treatment duration. Among the 184 patients identified, 44 (24%) developed confirmed progression independent of relapse activity under natalizumab irrespective of the Expanded Disability Status Scale score at natalizumab onset. Time to confirmed progression independent of relapse activity was not affected by Expanded Disability Status Scale at natalizumab onset (categorized by Expanded Disability Status Scale score ≤3.5 versus >3.5) nor by duration of disease nor by duration of therapy. Confirmed progression independent of relapse activity occurred earlier in the disease course in patients with an earlier natalizumab therapy onset with regard to disease duration. A stepwise forward regression analysis revealed disease duration as the main factor for confirmed progression independent of relapse activity development (P = 0.005). Taken together, confirmed progression independent of relapse activity occurs in a substantial proportion of patients on long-term natalizumab treatment and independent of Expanded Disability Status Scale score at natalizumab onset. Our findings suggest that patients who are initiated on natalizumab early during disease course, usually in order to treat an aggressive clinical phenotype, have a higher risk of early confirmed progression independent of relapse activity.

Brain and Mind Centre University of Sydney Camperdown NSW 2050 Australia

Data Integration for Future Medicine Consortium LMU Hospital Ludwig Maximilians University Munich Germany

Department of Neurology Medical Faculty University Hospital Heinrich Heine University 40225 Düsseldorf Germany

Department of Neurology Medical University of Vienna 1090 Vienna Austria

Department of Neurology Palacky University in Olomouc 779 00 Olomouc Czech Republic

Institute of Clinical Neuroimmunology LMU Hospital Ludwig Maximilians University Munich 81377 Munich Germany

Neurologie in Meerbusch 40667 Meerbusch Germany

Zobrazit více v PubMed

Lublin FD, Reingold SC, Cohen JA, et al.Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83(3):278–286. PubMed PMC

Frischer JM, Bramow S, Dal-Bianco A, et al.The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175–1189. PubMed PMC

Miller DH, Khan OA, Sheremata WA, et al.A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23. PubMed

Polman CH, O'Connor PW, Havrdova E, et al.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. PubMed

Rudick RA, Stuart WH, Calabresi PA, et al.Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923. PubMed

Mazdeh M, Hosseini S, Taheri M, Ghafouri-Fard S.. The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: A prospective cohort study. Clin Transl Med. 2018;7(1):38. PubMed PMC

Zhovtis Ryerson L, Frohman TC, Foley J, et al.Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(8):885–889. PubMed

O'Connor P, Miller D, Riester K, et al.Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler. 2005;11(5):568–572. PubMed

Kapoor R, Ho P-R, Campbell N, et al.Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17(5):405–415. PubMed

Zivadinov R, Hojnacki D, Bergsland N, et al.Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. Eur J Neurol. 2016;23(6):1101–1109. PubMed

Brown JWL, Coles A, Horakova D, et al.Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–187. PubMed PMC

Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ.. The 2013 clinical course descriptors for multiple sclerosis: A clarification. Neurology. 2020;94(24):1088–1092. PubMed PMC

Lorscheider J, Buzzard K, Jokubaitis V, et al.Defining secondary progressive multiple sclerosis. Brain. 2016;139(Pt 9):2395–2405. PubMed

Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA.. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(13):1246–1252. PubMed PMC

Confavreux C, Vukusic S, Adeleine P.. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain. 2003;126(Pt 4):770–782. PubMed

Confavreux C, Vukusic S, Moreau T, Adeleine P.. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430–1438. PubMed

Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y.. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73(20):1616–1623. PubMed PMC

Cree BAC, Hollenbach JA, Bove R, et al.Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653–666. PubMed PMC

Lorscheider J, Benkert P, Schädelin S, et al. Disability progression unrelated to relapses in relapsing-remitting multiple sclerosis: Insights from the Swiss multiple sclerosis cohort study. https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279536/johannes.lorscheider.disability.progression.unrelated.to.relapses.in.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1. Accessed 20 April 2021.

Polman CH, Reingold SC, Banwell B, et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. PubMed PMC

Kappos L, Butzkueven H, Wiendl H, et al.Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2018;24(7):963–973. PubMed PMC

Kappos L, Wolinsky JS, Giovannoni G, et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132–1140. PubMed PMC

Butzkueven H, Kappos L, Wiendl H, et al.Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91(6):660–668. PubMed PMC

Tremlett H, Yinshan Z, Devonshire V.. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314–324. PubMed

Confavreux C, Vukusic S.. Natural history of multiple sclerosis: A unifying concept. Brain. 2006;129(Pt 3):606–616. PubMed

Ford C, Goodman AD, Johnson K, et al.Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342–350. PubMed PMC

Kappos L, Edan G, Freedman MS, et al.The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87(10):978–987. PubMed PMC

Cree BAC, Gourraud P-A, Oksenberg JR, et al.Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499–510. PubMed PMC

Fambiatos A, Jokubaitis V, Horakova D, et al.Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler. 2019;26(1):79–90. PubMed

Kappos L, Bar-Or A, Cree BAC, et al.Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273. PubMed

Fisniku LK, Brex PA, Altmann DR, et al.Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131(Pt 3):808–817. PubMed

Genovese AV, Hagemeier J, Bergsland N, et al.Atrophied brain T2 lesion volume at MRI is associated with disability progression and conversion to secondary progressive multiple sclerosis. Radiology. 2019;293(2):424–433. PubMed PMC

Chung KK, Altmann D, Barkhof F, et al.A 30-year clinical and magnetic resonance imaging observational study of multiple sclerosis and clinically isolated syndromes. Ann Neurol. 2020;87(1):63–74. PubMed PMC

Multiple sclerosis: emerging epidemiological trends and redefining the clinical course

Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies